Clinical Trial Update: KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is a phase 1/2 clinical trial evaluating a KRAS neoantigen nanovaccine as adjuvant therapy for colorectal cancer and pancreatic cancer, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Cancer

Drugs mentioned

• KRAS Neoantigen Nanovaccine

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Colorectal Cancer, Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING